Flag of the European Union EU Clinical Trials Register Help

Clinical trials for DSS

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    63 result(s) found for: DSS. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2019-000560-22 Sponsor Protocol Number: MT-12 Start Date*: Information not available in EudraCT
    Sponsor Name:ALK-Abelló A/S
    Full Title: A one-year placebo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivi...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis induced by house dust mites
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) SK (Completed) DE (Completed) PL (Completed) ES (Ongoing) BG (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000120-15 Sponsor Protocol Number: AV-G-02 Start Date*: 2011-11-08
    Sponsor Name:ALK-Abelló A/S
    Full Title: AVANZ Phleum pratense maintenance dose
    Medical condition: Grass pollen induced allergic rhinoconjunctivitis with or without asthma.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002543-28 Sponsor Protocol Number: MIRA1 Start Date*: 2020-01-15
    Sponsor Name:MEGAINPHARM GmbH
    Full Title: A multi-center, randomized, placebo-controlled, double-blind, dose-finding clinical trial investigating the short-term relief of symptoms of acute pharyngitis such as throat soreness pain and diffi...
    Medical condition: Acute Pharyngitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003864-20 Sponsor Protocol Number: P05234 Start Date*: 2009-04-14
    Sponsor Name:Schering Plough Research Institute, a Division of Schering Corporation
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia artemisiifolia) Sublingual Tablet (SCH 39641) in ...
    Medical condition: Rhinoconjunctivitis due to ragweed allergy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-004827-22 Sponsor Protocol Number: BM41-VD3 Start Date*: 2017-07-25
    Sponsor Name:Academic Medical Center
    Full Title: A randomized, double-blind, placebo-controlled, double-dummy study to determine the safety/tolerability of a simultaneous subcutaneous treatment of BM41 and vitamin D 3 in patients with moderate to...
    Medical condition: moderate to severe allergic rhinitis/rhino-conjunctivitis caused by birch pollen (with or without concomitant mild to moderate persistent asthma)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000408-13 Sponsor Protocol Number: PQGrass309 Start Date*: 2020-09-18
    Sponsor Name:Allergy Therapeutics (UK) Ltd.
    Full Title: A randomised, double-blind, placebo-controlled exploratory study to explore the efficacy and safety of PQ Grass 27600 SU in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induc...
    Medical condition: seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002277-38 Sponsor Protocol Number: MT-06 Start Date*: 2011-10-06
    Sponsor Name:ALK-Abelló A/S
    Full Title: A one-year trial evaluating the efficacy and safety of the ALK house dust mite allergy immunotherapy tablet in adult subjects with house dust mite allergic rhinitis
    Medical condition: allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10034382 Perennial allergic rhinitis LLT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001723 Allergic rhinitis LLT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001724 Allergic rhinitis (excl hay fever) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) LV (Completed) DK (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004341-27 Sponsor Protocol Number: MK-3641-008 Start Date*: 2016-01-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a Histo...
    Medical condition: Rhinoconjunctivitis due to ragweed allergy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) HR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005717-80 Sponsor Protocol Number: FAB117-CT-01 Start Date*: 2016-05-29
    Sponsor Name:Ferrer Internacional S.A
    Full Title: Clinical trial of phase 1/2 to evaluate the feasibility, safety, tolerability and preliminary efficacy of the administration of FAB117-HC, a drug whose active ingredient is HC016, allogeneic adipos...
    Medical condition: Patients with acute traumatic spinal cord injury
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004863 10043064 T7-T12 level spinal cord injury, unspecified LLT
    18.1 100000004863 10043046 T1-T6 level spinal cord injury, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004353-32 Sponsor Protocol Number: GECP16/06 Start Date*: 2017-09-01
    Sponsor Name:Spanish Lung Cancer Group (SLCG/GECP)
    Full Title: Survival, quality of life and self-reported outcomes of elderly patients with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (MK-3475) in the first line setting
    Medical condition: First line treatment in PD-L1 positive advanced non-small cell lung cancer patients
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-003878-33 Sponsor Protocol Number: MOL-PAP-002 Start Date*: 2016-01-28
    Sponsor Name:Savara ApS
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients
    Medical condition: Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037316 Pulmonary alveolar proteinosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) NL (Completed) DE (Completed) GR (Completed) ES (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004363-39 Sponsor Protocol Number: MT-11 Start Date*: 2018-03-15
    Sponsor Name:ALK-Abelló A/S
    Full Title: A phase III trial evaluating the efficacy and safety of the house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet in children and adolescents (5-17 years) with HDM allergic asthma
    Medical condition: House Dust Mite (HDM) Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Temporarily Halted) HU (Completed) BG (Completed) DK (Completed) FR (Completed) PL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-001532-65 Sponsor Protocol Number: LGT03-19 Start Date*: 2019-09-12
    Sponsor Name:LOFARMA S.P.A.
    Full Title: A prospective, multicenter, double-blind, placebo-controlled randomized study to assess efficacy and safety of LAIS® Grass pollen tablets in patients with seasonal grass pollen-induced allergic rhi...
    Medical condition: seasonal grass pollen-induced allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036019 Pollen allergy LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001077-87 Sponsor Protocol Number: IJB-RT-HNC-001 Start Date*: 2019-08-08
    Sponsor Name:Institut Jules Bordet
    Full Title: Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced head and neck cancer patients t...
    Medical condition: advanced head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002429-12 Sponsor Protocol Number: UC_0160/1613 Start Date*: 2018-01-31
    Sponsor Name:UNICANCER
    Full Title: PERSONALIZED TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PATIENTS ACCORDING TO CIRCULATING TUMOR CELLS KINETIC DURING CHEMOTHERAPY
    Medical condition: Metastatic castrate-resistant prostate cancer requiring initiation of chemotherapy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-005603-25 Sponsor Protocol Number: WO29636 Start Date*: 2015-07-30
    Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED, HIGH RISK MUSCLE INVASIVE BLADDER C...
    Medical condition: Muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FI (Completed) CZ (Completed) DE (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) FR (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004372-17 Sponsor Protocol Number: TT-06 Start Date*: 2021-04-20
    Sponsor Name:ALK-Abelló A/S
    Full Title: Efficacy and safety of the SQ tree sublingual immunotherapy tablet in children and adolescents (5 through 17 years of age) with moderate to severe allergic rhinitis and/or conjunctivitis induced by...
    Medical condition: Tree pollen induced allergic rhinitis and/or conjuctivitis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) HU (Completed) SK (Completed) PL (Completed) AT (Completed) DK (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005452-38 Sponsor Protocol Number: D910PC00001 Start Date*: 2021-11-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With En...
    Medical condition: Cisplatin ineligible patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10005004 Bladder cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003626-40 Sponsor Protocol Number: CA209-274 Start Date*: 2016-07-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
    Medical condition: Subjects with High Risk Invasive Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) SE (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) RO (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000051-27 Sponsor Protocol Number: PM/0041 Start Date*: 2016-09-22
    Sponsor Name:HAL Allergy B.V.
    Full Title: A randomized, double-blind, placebo-controlled (DBPC) parallel-group multi-centre study to assess the efficacy and safety of PURETHAL Mites subcutaneous immunotherapy (SCIT) in patients with allerg...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis (ARC) caused by house dust mite (HDM) allergy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004855 10001724 Allergic rhinitis (excl hay fever) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) HU (Completed) ES (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 20:36:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA